The North America Lateral Flow Assays Market was valued at USD 2,130 Million in 2025 and is expected to reach USD 4,380 Million by 2035, expanding at a CAGR of 6.7% from 2024 to 2035. This growth is driven by technological advancements, rising demand for point-of-care diagnostics, and a growing awareness of infectious disease control.
The economic impact of tariffs on "North America Lateral Flow Assays Market".
Market Growth Drivers
Rising Prevalence of Chronic and Infectious Diseases: The increasing incidence of chronic illnesses such as cardiovascular diseases and diabetes, along with the rise in infectious disease outbreaks, is significantly boosting the demand for lateral flow assay kits. Abbott Laboratories, for example, reported a surge in COVID-19 and influenza diagnostic revenues post-2020, underlining the necessity for rapid and accurate point-of-care solutions to cater to such widespread health concerns.
Expanding Applications in Food Safety and Environmental Testing: Beyond healthcare, companies such as Danaher Corporation (through Cepheid) are extending lateral flow assay technologies into food safety and environmental testing. Growing regulatory scrutiny and public demand for safer food products are contributing to the adoption of lateral flow assays across various industries, boosting the market growth prospects.
Market Trends
Integration with Digital Technologies: A major trend is the integration of lateral flow assays with digital and connected devices to enable quantitative reading and data sharing. For instance, BD (Becton, Dickinson and Company) has developed digital readers for its lateral flow assay kits, allowing for improved test sensitivity, record keeping, and remote patient monitoring. These advancements support telemedicine and decentralized diagnostics.
Development of Multiplex Assays: Companies like QuidelOrtho have recently launched multiplex lateral flow assays that can simultaneously detect multiple pathogens, such as influenza and SARS-CoV-2, in a single test. This trend addresses the need for efficient diagnostic tools in hospital and point-of-care settings, reducing costs and helping clinicians make faster, more informed decisions.
Market Opportunities
Expansion into Home Testing: The growing public acceptance of home-based testing after the COVID-19 pandemic presents an opportunity for market players like Abbott and BD to develop and market more user-friendly, FDA-approved at-home lateral flow assay kits.
Emerging Demand in Veterinary Diagnostics: Companies such as Zoetis are exploring the lateral flow assay market to address infectious diseases in animals, opening new revenue streams in the North American veterinary healthcare sector.
North America Lateral Flow Assays Market Revenue (USD Million), 2020-2035
The chart demonstrates a steady upward trend in the North America Lateral Flow Assays Market revenue from 2020 to 2035. After a significant leap in 2020 and 2021 driven by the pandemic response, the market stabilized but maintained robust growth as a result of expanding applications and ongoing diagnostic needs. The market grew from USD 1,250 Million in 2020 to USD 2,130 Million by 2025, and is projected to more than double to USD 4,380 Million by 2035. Technological advancements, increasing patient awareness, and new product launches by major companies underpin this sustained growth trajectory.
North America Lateral Flow Assays Market Share by Region (%), 2025
The pie chart shows the regional market share of the North America Lateral Flow Assays Market in 2025. The United States dominates with 72% of the market, attributable to higher healthcare spending, strong industry presence, and greater adoption of diagnostic technologies. Canada holds 16%, bolstered by increasing investments in healthcare infrastructure and diagnostics. Mexico follows with 8%, as awareness and investment in diagnostics rise. The 'Rest of North America,' including the Caribbean and US territories, contributes 3%, while 'Others' account for the remaining 1%. The chart underscores the United States' leading influence and the opportunities for growth in other North American regions.
Recent Developments
In February 2024, Abbott announced the launch of its new BinaxNOW COVID-19 & Flu A+B at-home lateral flow test in the US, gaining an Emergency Use Authorization (EUA) from the FDA. This test simplifies the identification of multiple respiratory illnesses, increasing the convenience and speed of diagnosis for consumers.
In March 2024, BD (Becton, Dickinson and Company) entered into a collaboration with Scanwell Health to co-develop smartphone-enabled lateral flow diagnostic kits for at-home use. This partnership is focused on expanding BD’s LFA platform into telemedicine and decentralized care models.
In April 2024, QuidelOrtho introduced its Savanna Multiplex LFA platform in North America, enabling clinicians to detect multiple respiratory pathogens (including COVID-19, RSV, and Influenza) in a single test. The launch follows successful clinical studies and addresses the growing demand for efficient, comprehensive point-of-care diagnostics.
Press Releases